Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said the Food and Drug Administration approved the company''s bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months, reports the Associated Press. The disease is fairly rare in the United States, but those who get it develop symptoms quickly and can die in only a few days. Survivors can suffer mental disabilities, hearing loss and paralysis. The company said this is the first U.S. approval for a bacterial meningitis vaccine for the age group between 9 months and 23 months. Menactra was already approved for people ages 11 through 55 and children between 2 and 10 years old.